Cefotaxime

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

39 Suppliers, 14 USDMF, 16 CEP/COS, 1 JDMF, 6 EU WC, 7 KDMF, 1 NDC API, 21 Listed Suppliers

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Exports

INTERMEDIATES

2 Suppliers

2 Suppliers

DOSSIERs // Finished Dosage Forms

205 Dossiers, 40 FDA Orange Book, 56 Europe, 2 Canada, 2 Australia, 25 South Africa, 80 Listed Dossiers

DRUG PRODUCT COMPOSITION

INJECTABLE;INJECTION - EQ 10GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

GLOBAL SALES INFORMATION

7 US Medicaid Prescriptions, 38 Finished Drug Prices

MARKET PLACE

19 APIs, 10 DOSSIERS // FDF

REF. STANDARDS & IMPURITIES

3 EDQM, 2 USP, 2 Others

DIGITAL CONTENT

6 News

6 News

Latest U.S. Prescription Data for Drugs containing Cefotaxime under Medicare's Part D Prescription Drug Program. Original Data: Centers for Medicare & Medicaid Services Website

Cefotaxime

Synopsis

Chemistry

APIs // Active Pharmaceutical Ingredients

39 Suppliers

14 USDMF

16 CEP/COS

1 JDMF

6 EU WC

7 KDMF

1 NDC API

21 Listed Suppliers

PRICE INFORMATION

API Reference Price

API Exports

API Imports

FDF Exports

INTERMEDIATES

2 Suppliers

DOSSIERs // Finished Dosage Forms

205 Dossiers

40 FDA Orange Book

56 Europe

2 Canada

2 Australia

25 South Africa

80 Listed Dossiers

DRUG PRODUCT COMPOSITION

INJECTABLE;INJECTION - EQ 10GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

GLOBAL SALES INFORMATION

7 US Medicaid Prescriptions

38 Finished Drug Prices

MARKET PLACE

19 APIs

10 DOSSIERS // FDF

REF. STANDARDS & IMPURITIES

3 EDQM

2 USP

2 Others

DIGITAL CONTENT

6 News

U.S. MEDICAID PRESCRIPTIONS

Cefotaxime Sodium

2019

12

13

172

U.S. MEDICAID PRESCRIPTIONS

Cefotaxime Sodium

2018

18

27

630

U.S. MEDICAID PRESCRIPTIONS

Cefotaxime Sodium

2017

21

32

637

U.S. MEDICAID PRESCRIPTIONS

Cefotaxime Sodium

2016

63

98

4,938

U.S. MEDICAID PRESCRIPTIONS

Cefotaxime Sodium

2015

56

113

7,054

U.S. MEDICAID PRESCRIPTIONS

CEFOTAXIME SODIUM

2014

124

198

INJECTABLE;INJECTION - EQ 10GM BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - EQ 1GM BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - EQ 2GM BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - EQ 500MG BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons